Translational Centers Using Microphysiologic Systems for Infectious Diseases
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The National Institute of Allergy and Infectious Diseases, under the Department of Health and Human Services, is forecasting an opportunity to support the development of human microphysiologic systems for infectious disease research and the creation of therapeutics or biological products. These in vitro platforms are designed to mimic human physiological processes and organ functions, aiming to reduce reliance on animal testing and establish human tissue models that are acceptable to regulatory bodies like the FDA. The program focuses on accelerating the adoption of these systems by drug and biological product developers to enhance basic research and product development. This initiative is authorized under the Public Health Service Act and relevant federal regulations, with administrative oversight provided by the Division of Microbiology and Infectious Diseases.
General Info
Place of Performance
Not specifiedSet-Aside
Documents
0AI Contract Breakdown
Uniform Contract FormatNo documents to break down
The breakdown needs solicitation documents. None were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance its mission by supporting the development of human microphysiologic systems (MPS) for infectious disease research and the development of therapeutics or biological products. MPS are in vitro platforms composed of cells or tissues maintained in a microenvironment designed to mimic the physiological aspects of in vivo tissue or organ function. There is growing support for the development of MPS for basic research at NIH and regulatory pathways at the FDA with the aim of reducing the use of animals in research and generating human tissue models that can be used to study human physiological processes. However, MPS development has not focused on their use in studies of infectious diseases or for product development. The goal of this program is to accelerate the use of MPS for infectious diseases and product development, promoting adoption for use by developers of drugs and biological products and their regulatory acceptance. Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.
Similar Contracts
Same NAICS industry code
More opportunities from Department Of Health And Human Services → National Institutes Of Health
Same awarding agency
Prepare for this forecast
Research this forecast and prepare for the solicitation
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 750+ contractors already using CLEATUS
